Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Solange Peters

Showing results (221-230 of 362) with videos related to

Pageof 37
Sort By:
Revue Medicale Suisse|January 22, 2020
[Advances in Oncology 2019]Anastasia Vernadou, Nabila Ferahta, Nuria Mederos, et al.
Nature Communications|November 11, 2023
Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trialSun Min Lim, Solange Peters, Ana Laura Ortega Granados, et al.
Clinical Lung Cancer|December 21, 2016
Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 TrialOliver Gautschi, Sacha I Rothschild, Qiyu Li, et al.
Lung Cancer (Amsterdam, Netherlands)|May 4, 2023
Spatial profiling of the microenvironment reveals low intratumoral heterogeneity and STK11-associated immune evasion in therapy-naïve lung adenocarcinomasHannah Goldschmid, Klaus Kluck, Markus Ball, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 5, 2025
Treatment-Free Survival Over 6 Years of Follow-up in Patients With Metastatic NSCLC Treated With First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in CheckMate 227 Part 1Solange Peters, Meredith M Regan, Luis G Paz-Ares, et al.
The Lancet. Oncology|October 2, 2025
Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysisAlessandro Di Federico, Sara Stumpo, Francesco Mantuano, et al.
Chinese Medical Journal|December 22, 2025
First-line atezolizumab monotherapy vs. single-agent chemotherapy in patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum-based therapy: Analysis of the IPSOS Asian subpopulationBaohui Han, Solange Peters, Anh Tuan Le, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 24, 2025
Advancing Lung Cancer Staging: Integrating IASLC Recommendations and Bioinformatics to Delineate Tumor OriginsMichael Allgäuer, Klaus Kluck, Petros Christopoulos, et al.
Lung Cancer (Amsterdam, Netherlands)|April 3, 2022
First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743Arnaud Scherpereel, Scott Antonia, Yolanda Bautista, et al.
Cancer Cell|May 20, 2020
TERAVOLT: Thoracic Cancers International COVID-19 CollaborationJennifer G Whisenant, Annalisa Trama, Valter Torri, et al.
Pageof 37

Showing results (221-230 of 362) with videos related to

Sort By:
Pageof 37
Revue Medicale Suisse|January 22, 2020
[Advances in Oncology 2019]Anastasia Vernadou, Nabila Ferahta, Nuria Mederos, et al.
Nature Communications|November 11, 2023
Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trialSun Min Lim, Solange Peters, Ana Laura Ortega Granados, et al.
Clinical Lung Cancer|December 21, 2016
Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 TrialOliver Gautschi, Sacha I Rothschild, Qiyu Li, et al.
Lung Cancer (Amsterdam, Netherlands)|May 4, 2023
Spatial profiling of the microenvironment reveals low intratumoral heterogeneity and STK11-associated immune evasion in therapy-naïve lung adenocarcinomasHannah Goldschmid, Klaus Kluck, Markus Ball, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 5, 2025
Treatment-Free Survival Over 6 Years of Follow-up in Patients With Metastatic NSCLC Treated With First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in CheckMate 227 Part 1Solange Peters, Meredith M Regan, Luis G Paz-Ares, et al.
The Lancet. Oncology|October 2, 2025
Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysisAlessandro Di Federico, Sara Stumpo, Francesco Mantuano, et al.
Chinese Medical Journal|December 22, 2025
First-line atezolizumab monotherapy vs. single-agent chemotherapy in patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum-based therapy: Analysis of the IPSOS Asian subpopulationBaohui Han, Solange Peters, Anh Tuan Le, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 24, 2025
Advancing Lung Cancer Staging: Integrating IASLC Recommendations and Bioinformatics to Delineate Tumor OriginsMichael Allgäuer, Klaus Kluck, Petros Christopoulos, et al.
Lung Cancer (Amsterdam, Netherlands)|April 3, 2022
First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743Arnaud Scherpereel, Scott Antonia, Yolanda Bautista, et al.
Cancer Cell|May 20, 2020
TERAVOLT: Thoracic Cancers International COVID-19 CollaborationJennifer G Whisenant, Annalisa Trama, Valter Torri, et al.
Pageof 37